Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 8, 2010, Pages 907-912

  Ebers, George C ^a   Traboulsee, A ^b   Li, D ^b   Langdon, D ^c   Reder, A T ^d   Goodin, D S ^e   Bogumil, T ^f   Beckmann, K ^g   Wolf, C ^g   Konieczny, A ^g  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BAYER CORPORATION   (United States)

^g BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; PLACEBO; BETA INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT DURATION; AGED; BIOASSAY; DISABILITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME;

AGED; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77955762153     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.204123     Document Type: Article

References (32)

1. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28.
2. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
3. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82. (Pubitemid 32488815)
4. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53. (Pubitemid 44454583)
5. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
6. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
7. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76.
8. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
9. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
10. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60. (Pubitemid 34457761)
11. Panitch H, Goodin DS, Francis G, et al. Evidence of Interferon Dose-response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-506.
12. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23. (Pubitemid 36026342)
13. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910. (Pubitemid 43313657)
14. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23.
15. Wolinsky JS, Narayana PA, Johnson KP. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis. MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Mult Scler 2001;7:33-41.
16. Paolillo A, Pozzilli C, Giugni E, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Eur J Neurol 2002;9:645-55. (Pubitemid 36961292)
17. Clanet M, Kappos L, Hartung HP, et al. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler 2004;10:139-44.
18. Herndon RM, Rudick RA, Munschauer FE, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex® treatment in patients with multiple sclerosis. Mult Scler 2005;11:409-19.
19. Rudick RA, Cutter GR, Baier M, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis. Mult Scler 2005;11:626-34. (Pubitemid 41685131)
20. Ford CC, Johnson KP, Lisak RP, et al. Copaxone Study Group. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12:309-20.
21. Ebers G, Reder A, Traboulsee A, et al. for the investigators of the 16-Year Long-Term Follow-Up of the Original Interferon b1b Trial in Multiple Sclerosis. Design and Lessons from a 16-Year Observational Study. Clin Ther 2009;31:1724-36.
22. Paty DW, Li DK. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7.
23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
24. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-82.
25. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort. A 10-year follow-up study. Neurology 2004;62:51-9.
26. Tremlett HL, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously expected. Neurology 2006;66:172-7. (Pubitemid 43970148)
27. Noseworthy JH. How much can we learn from long-term extension trials in multiple sclerosis? Neurology 2006;67:930-1.
28. Ebers GC, Heigenhauser L, Daumer M, et al. Disability as an outcome in MS clinical trials. Neurology 2008;71:624-31.
29. Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-4.
30. Ebers GC. Natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;71(Suppl 2):ii16-9.
31. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-9. (Pubitemid 28302357)
32. Roxburgh RHSR, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-51.